We receives Hong Kong patent for biological control of the house dust mite
post-template-default,single,single-post,postid-10054,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Evolution Biotechnologies receives Hong Kong patent for biological control of the house dust mite

Bedford, UK, April 3rd 2020

Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company pioneering the use of biological control to benefit human health, today reports that it has received notice of award of Hong Kong patent number 1252537, “Acaricides”.

This patent protects the use of replicating biological agents for control of house dust mites, a key cause of asthma and other allergic conditions, and follows on from the award of European patent 3331366. Examination of applications proceeding from the underlying PCT application GB2016/052455 is proceeding in other jurisdictions.

Dr. David Harper, Evolution’s CEO, said “this represents a key part of our strategy and highlights the importance that we place on expanding our activities in Asian markets. This award represents further progress in protecting Evolution’s key technology, for the control of house dust mite infestations as a preventative for asthma. Asthma is of course of particular relevance during the current COVID-19 outbreak, where respiratory conditions are known to increase the risks of serious complications.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial targetis the development of a novel, self-amplifying biological control forthe house dust mite, an expanding multi-billion dollar market with high value and significant unmet need. Asthma is a worldwide, chronic disease and house dust mite allergens are key to both sensitization and the triggering of attacks. The number of asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed $100 billion in the EU and US alone.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”.Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of this proven approach into high value markets with unmet clinical need.

Forward-looking statements

This document contains certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.com

Website: www.evolutionbiotech.com

No Comments

Sorry, the comment form is closed at this time.